A trial of adavosertib with chemotherapy for ovarian cancer

Cancer type:

Ovarian cancer
Secondary cancers

Status:

Results

Phase:

Phase 2

This trial looked at adavosertib alongside paclitaxel and carboplatin for ovarian cancer that had come back. 

It was for women:

  • who had cancer that had responded to platinum chemotherapy Open a glossary item in the past
  • whose cancer cells had a particular change (mutation) in the p53 gene Open a glossary item

Adavosertib is also called MK-1775 and AZD1775.

This trial was open for people to join between 2013 and 2014. The team published the results in 2020. There is a link to more information in the ‘Summary of results’ section below.

More about this trial

Please note, we talk about ovarian cancer in this summary, but it was also for women with fallopian tube cancer or primary peritoneal cancer.

Doctors often treat ovarian cancer with surgery and chemotherapy. The drugs they use include paclitaxel and carboplatin.

Sometimes the cancer starts to grow again. Doctors wanted to find out if adavosertib could help people in this situation. Adavosertib is a type of targeted cancer treatment called a cancer growth blocker. It stops the signals that cancer cells need to divide and grow.

The people taking part were put into a treatment group at random:

  • half had paclitaxel, carboplatin and adavosertib
  • half had paclitaxel, carboplatin and a dummy drug (placebo)

The main aims of the trial were to find out:

  • if adavosertib is helpful for ovarian cancer that has come back
  • more about the side effects

Summary of results

We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.

There is more information about the results in the link below.

Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.

A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive TP53-mutant Ovarian Cancer 
A M Oza and others
Clinical Cancer Research, 2020. Volume  26, issue 18, pages 4767 - 4776.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Susie Banerjee

Supported by

Experimental Cancer Medicine Centre (ECMC)
Merck, Sharp & Dohme
NIHR Clinical Research Network: Cancer

If you have questions about the trial please contact our cancer information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 10187

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think